<!DOCTYPE html>
<html>
<head>
<title>XENICAL, INN-orlistat</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Xenical 120 mg hard capsules </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each hard capsule contains 120 mg orlistat. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For a full list of excipients, see 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hard capsule.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The capsule has a turquoise cap and turquoise body bearing the imprint of &#x201c;XENICAL 120&#x201d;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a body mass index (BMI) greater or equal to 30 kg/m&#xb2;, or overweight patients (BMI &gt; 28 kg/m&#xb2;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with associated risk factors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">least 5 % of the body weight as measured at the start of therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adults  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be omitted.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily intake of fat, carbohydrate and protein should be distributed over three main meals. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Doses of orlistat above 120 mg three times daily have not been shown to provide additional benefit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing. Upon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">discontinuation of therapy, faecal fat content usually returns to pre-treatment levels, within 48 to 72 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The effect of orlistat in patients with hepatic and/or renal impairment, children and elderly patients has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not been studied.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no relevant indication for use of Xenical in children. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Chronic malabsorption syndrome. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cholestasis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical trials, the decrease in bodyweight with orlistat treatment was less in type II diabetic patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than in non-diabetic patients. Antidiabetic medicinal product treatment may have to be closely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored when taking orlistat. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Co-administration of orlistat with ciclosporin is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be advised to adhere to the dietary recommendations they are given (see section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The possibility of experiencing gastrointestinal adverse reactions (see section 4.8) may increase when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orlistat is taken with a diet high in fat (e.g. in a 2000 kcal/day diet, &gt; 30 % of calories from fat equates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to &gt; 67 g of fat). The daily intake of fat should be distributed over three main meals. If orlistat is taken </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a meal very high in fat, the possibility of gastrointestinal adverse reactions may increase.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of rectal bleeding have been reported with Xenical. Prescribers should investigate further in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">case of severe and/or persistent symptoms. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of an additional contraceptive method is recommended to prevent possible failure of oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraception that could occur in case of severe diarrhoea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Coagulation parameters should be monitored in patients treated with concomitant oral anticoagulants </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.5 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to renal failure. This risk is increased in patients with underlying chronic kidney disease and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">volume depletion (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mechanism, although not proven, may involve a decreased absorption of iodine salts and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levothyroxine (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antiepileptics patient: Orlistat may unbalance anticonvulsant treatment by decreasing the absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of antiepileptic drugs, leading to convulsions (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antiretrovirals for HIV: Orlistat may potentially reduce the absorption of antiretroviral medicines for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV and could negatively affect the efficacy of antiretroviral medications for HIV (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ciclosporin </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A decrease in ciclosporin plasma levels has been observed in a drug-drug-interaction study and also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported in several cases, when orlistat was administered concomitantly. This can lead to a decrease of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressive efficacy. Therefore the combination is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However, if such concomitant use is unavoidable, more frequent monitoring of ciclosporin blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels should be performed both after addition of orlistat and upon discontinuation of orlistat in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ciclosporin treated patients. Ciclosporin blood levels should be monitored until stabilised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Acarbose  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the absence of pharmacokinetic interaction studies, the concomitant administration of orlistat with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acarbose should be avoided.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Oral anticoagulants </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When warfarin or other anticoagulants are given in combination with orlistat, international normalised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ratio (INR) values should be monitored (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fat soluble vitamins</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E and K). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The vast majority of patients receiving up to four full years of treatment with orlistat in clinical studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">had vitamin A, D, E and K and beta-carotene levels that stayed within normal range. In order to ensure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adequate nutrition, patients on a weight control diet should be advised to have a diet rich in fruit and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vegetables and use of a multivitamin supplement could be considered. If a multivitamin supplement is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended, it should be taken at least two hours after the administration of orlistat or at bedtime. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Amiodarone</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A slight decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">limited number of healthy volunteers who received orlistat concomitantly. In patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">amiodarone treatment, the clinical relevance of this effect remains unknown but may become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinically relevant in some cases. In patients receiving concomitant amiodarone treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reinforcement of clinical and ECG monitoring is warranted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">e.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, these patients should be monitored for possible changes in the frequency and/or severity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">convulsions.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mechanism, although not proven, may involve a decreased absorption of iodine salts and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levothyroxine (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are some case reports of reduced efficacy of antiretroviral HIV medicines, antidepressants </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antipsychotics (including lithium) and benzodiazepines coincidental to the initiation of orlistat </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment in previously well-controlled patients.  Therefore orlistat treatment should only be initiated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after careful consideration of the possible impact in these patients.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lack of interactions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No interactions with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phenytoin, phentermine, pravastatin, nifedipine Gastrointestinal Therapeutic System (GITS), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nifedipine slow release, sibutramine or alcohol have been observed. The absence of these interactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">has been demonstrated in specific drug-drug-interaction studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The absence of an interaction between oral contraceptives and orlistat has been demonstrated in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">specific drug-drug interaction studies. However, orlistat may indirectly reduce the availability of oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraceptives and lead to unexpected pregnancies in some individual cases. An additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraceptive method is recommended in case of severe diarrhoea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For orlistat no clinical data on exposed pregnancies are available. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">embryonal/foetal development, parturition or postnatal development (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Caution should be exercised when prescribing to pregnant women. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As it is not known whether orlistat is secreted into human milk, orlistat is contra-indicated during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">breast-feeding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Xenical has no influence on the ability to drive and use machines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions to orlistat are largely gastrointestinal in nature. The incidence of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased with prolonged use of orlistat.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse events are listed below by system organ class and frequency.  Frequencies are defined as: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very common (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10), common (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/100 to &lt;1/10), uncommon (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/1,000 to &lt;1/100), rare (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to &lt;1/1,000) and very rare (&lt;1/10,000) including isolated reports.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table of undesirable effects (first year of treatment) is based on adverse events that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurred at a frequency of &gt; 2 % and with an incidence </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1 % above placebo in clinical trials of 1 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 years duration: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:132pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">System organ class </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:353pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reaction/event </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:89pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:89pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:239pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upper respiratory infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lower respiratory infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:239pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal pain/discomfort </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oily spotting from the rectum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flatus with discharge </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Faecal urgency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fatty/oily stool </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flatulence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Liquid stools </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oily evacuation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Increased defecation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rectal pain/discomfort </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Soft stools </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Faecal incontinence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal distension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tooth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gingival disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:239pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Urinary tract infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycemia* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections and infestations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:217pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Influenza </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:239pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:239pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Menstrual irregularity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psychiatric disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:239pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Anxiety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* only unique treatment adverse events that occurred at a frequency of &gt; 2 % and with an incidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1 % above placebo in obese type 2 diabetic patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a 4 year clinical trial, the general pattern of adverse event distribution was similar to that reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for the 1 and 2 year studies with the total incidence of gastrointestinal related adverse events occurring </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in year 1 decreasing year on year over the four year period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table of undesirable effects is based on post-marketing spontaneous reports, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therefore the frequency remains unknown: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:131pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">System organ class</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:363pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reaction</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Increase in liver transaminases and in alkaline  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phosphatase.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Decreased prothrombin, increased INR and  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">unbalanced anticoagulant treatment resulting in  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">variations of haemostatic parameters have been  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported in patients treated with anticoagulants in  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">association with orlistat (see section 4.4 and 4.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rectal bleeding  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diverticulitis  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pancreatitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">                                                          </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:515pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bullous eruptions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity (e.g. pruritus, rash, urticaria,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angioedema, bronchospasm and anaphylaxis)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cholelithiasis  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatitis that may be serious. Some fatal cases or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cases requiring liver transplantation have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oxalate nephropathy that may lead to renal failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#ff0000"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V*</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#c00000">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Single doses of 800 mg orlistat and multiple doses of up to 400 mg three times daily for 15 days have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been studied in normal weight and obese subjects without significant adverse findings. In addition, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses of 240 mg tid have been administered to obese patients for 6 months. The majority of orlistat </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">overdose cases received during post-marketing reported either no adverse events or adverse events that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are similar to those reported with recommended dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should a significant overdose of orlistat occur, it is recommended that the patient be observed for 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hours. Based on human and animal studies, any systemic effects attributable to the lipase-inhibiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">properties of orlistat should be rapidly reversible. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmaco-therapeutic group: Peripherally acting antiobesity agent, ATC code A08AB01. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">activity in the lumen of the stomach and small intestine by forming a covalent bond with the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the 2-year studies and the 4-year study, a hypocaloric diet was used in association with treatment in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">both the orlistat and the placebo treated groups. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pooled data from five 2 year studies with orlistat and a hypocaloric diet showed that 37 % of orlistat </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and 19 % of placebo patients demonstrated a loss of at least 5 % of their baseline body weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after 12 weeks of treatment. Of these, 49 % of orlistat treated patients and 40 % of placebo treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients went on to lose &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of their baseline body weight at one year. Conversely, of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failing to demonstrate a loss of 5 % of their baseline body weight after 12 weeks of treatment, only </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 % of orlistat treated patients and 2 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">% of placebo treated patients went on to lose &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline body weight at one year. Overall, after one year of treatment, the percentage of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">taking 120 mg orlistat who lost 10 % or more of their body weight was 20 % with orlistat 120 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to 8 % of patients taking placebo. The mean difference in weight loss with the drug </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to placebo was 3.2 kg.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data from the 4-year XENDOS clinical trial showed that 60 % of orlistat patients and 35 % of placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients demonstrated a loss of at least 5 % of their baseline body weight after 12 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Of these, 62 % of orlistat treated patients and 52 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">% of placebo treated patients went on to lose &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of their baseline body weight at one year. Conversely, of patients failing to demonstrate a loss of 5 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of their baseline body weight after 12 weeks of treatment, only 5 % of orlistat treated patients and 4 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of placebo treated patients went on to lose &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of their baseline body weight at one year. After </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 year of treatment, 41 % of the orlistat treated patients versus 21 % of placebo treated patients lost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of body weight with a mean difference of 4.4 kg between the two groups. After 4 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment 21 % of the orlistat treated patients compared to 10 % of the placebo treated patients had lost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of body weight, with a mean difference of 2.7 kg.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">More patients on orlistat or placebo lost baseline body weight of at least 5 % at 12 weeks or 10 % at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">one year in the XENDOS study than in the five 2-year studies. The reason for this difference is that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">five 2-year studies included a 4-week diet and placebo lead-in period during which patients lost on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">average 2.6 kg prior to commencing treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data from the 4-year clinical trial also suggested that weight loss achieved with orlistat delayed the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">development of type 2 diabetes during the study (cumulative diabetes cases incidences: 3.4 % in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orlistat group compared to 5.4 % in the placebo-treated group). The great majority of diabetes cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">came from the subgroup of patients with impaired glucose tolerance at baseline, which represented </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">21 % of the randomised patients. It is not known whether these findings translate into long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical benefits. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In obese type 2 diabetic patients insufficiently controlled by antidiabetic agents, data from four one-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">year clinical trials showed that the percentage of responders (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of body weight loss) was 11.3 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with orlistat as compared to 4.5 % with placebo. In orlistat-treated patients, the mean difference from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo in weight loss was 1.83 kg to 3.06 kg and the mean difference from placebo in HbA1c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction was 0.18 % to 0.55 %. It has not been demonstrated that the effect on HbA1c is independent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from weight reduction.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a multi-centre (US, Canada), parallel-group, double-blind, placebo-controlled study, 539 obese </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adolescent patients were randomised to receive either 120 mg orlistat (n=357) or placebo (n=182) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three times daily as an adjunct to a hypocaloric diet and exercise for 52 weeks. Both populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">received multivitamin supplements. The primary endpoint was the change in body mass index (BMI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from baseline to the end of the study. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The results were significantly superior in the orlistat group (difference in BMI of 0.86 kg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in favour </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of orlistat). 9.5 % of the orlistat treated patients versus 3.3 % of the placebo treated patients lost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 % of body weight after 1 year with a mean difference of 2.6 kg between the two groups. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">difference was driven by the outcome in the group of patients with &#x2265; 5 % weight loss after 12 weeks of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with orlistat representing 19 % of the initial population. The side effects were generally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">similar to those observed in adults. However, there was an unexplained increase in the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bone fractures (6 % versus 2.8 % in the orlistat and placebo groups, respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Absorption </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in normal weight and obese volunteers have shown that the extent of absorption of orlistat was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">minimal. Plasma concentrations of intact orlistat were non-measurable (&lt; 5 ng/ml) eight hours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following oral administration of orlistat. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In general, at therapeutic doses, detection of intact orlistat in plasma was sporadic and concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were extremely low (&lt; 10 ng/ml or 0.02 &#xb5;mol), with no evidence of accumulation, which is consistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with minimal absorption. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Distribution</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution cannot be determined because the drug is minimally absorbed and has no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">defined systemic pharmacokinetics. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> orlistat is &gt; 99 % bound to plasma proteins (lipoproteins </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and albumin were the major binding proteins). Orlistat minimally partitions into erythrocytes. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metabolism</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on animal data, it is likely that the metabolism of orlistat occurs mainly within the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gastrointestinal wall. Based on a study in obese patients, of the minimal fraction of the dose that was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">absorbed systemically, two major metabolites, M1 (4-member lactone ring hydrolysed) and M3 (M1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with N-formyl leucine moiety cleaved), accounted for approximately 42 % of the total plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M1 and M3 have an open beta-lactone ring and extremely weak lipase inhibitory activity (1000 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2500 fold less than orlistat respectively). In view of this low inhibitory activity and the low plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels at therapeutic doses (average of 26 ng/ml and 108 ng/ml respectively), these metabolites are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered to be pharmacologically inconsequential. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elimination </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in normal weight and obese subjects have shown that faecal excretion of the unabsorbed drug </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was the major route of elimination. Approximately 97 % of the administered dose was excreted in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">faeces and 83 % of that as unchanged orlistat. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The cumulative renal excretion of total orlistat-related materials was &lt; 2 % of the given dose. The time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to reach complete excretion (faecal plus urinary) was 3 to 5 days. The disposition of orlistat appeared </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to be similar between normal weight and obese volunteers. Orlistat, M1 and M3 are all subject to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">biliary excretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on conventional studies of safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reproduction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In animal reproductive studies, no teratogenic effect was observed. In the absence of a teratogenic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect in animals, no malformative effect is expected in man. To date, active substances responsible for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">malformations in man have been found teratogenic in animals when well-conducted studies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">performed in two species. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Capsule filling: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">microcrystalline cellulose (E460)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sodium starch glycolate (type A) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">povidone (E1201)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sodium laurilsulfate  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">talc </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Capsule shell: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gelatine  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indigo carmine (E132)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titanium dioxide (E171)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">edible printing ink (black iron oxide, ammonia solution concentrated, potassium hydroxide, shellac, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">propylene glycol) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blisters: Do not store above 25 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb0;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C. Store in original package and keep the blister in the outer carton in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">order to protect from light and moisture. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bottles: Do not store above 30 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb0;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C. Keep the container tightly closed in order to protect from moisture. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PVC/ PVDC blisters containing 21, 42 and 84 hard capsules. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Glass bottles with desiccant containing 21, 42 and 84 hard capsules. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No special requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CHEPLAPHARM Arzneimittel GmbH </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ziegelhof 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">17489 Greifswald </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Germany  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/98/071/001-006 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 29 July 1998 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 17 June 2008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this product is available on the website of the European Medicines Agency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
















</body>
</html> 

